823.23
2.41%
19.15
After Hours:
824.29
1.06
+0.13%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $823.23, with a volume of 2.48M.
It is up +2.41% in the last 24 hours and up +6.42% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$804.08
Open:
$808.41
24h Volume:
2.48M
Relative Volume:
0.63
Market Cap:
$778.66B
Revenue:
$40.86B
Net Income/Loss:
$8.37B
P/E Ratio:
89.00
EPS:
9.25
Net Cash Flow:
$-2.28B
1W Performance:
+7.42%
1M Performance:
+6.42%
6M Performance:
+4.21%
1Y Performance:
+27.68%
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
823.23 | 778.66B | 40.86B | 8.37B | -2.28B | 9.25 |
NVO
Novo Nordisk Adr
|
85.34 | 379.90B | 39.36B | 13.79B | 9.83B | 3.086 |
JNJ
Johnson Johnson
|
152.87 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
ABBV
Abbvie Inc
|
175.59 | 310.55B | 55.53B | 5.12B | 15.62B | 2.88 |
MRK
Merck Co Inc
|
98.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-10-24 | Resumed | BofA Securities | Buy |
Nov-15-24 | Initiated | Wolfe Research | Outperform |
Oct-17-24 | Initiated | Bernstein | Outperform |
Sep-13-24 | Resumed | Citigroup | Buy |
Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Oct-20-23 | Resumed | UBS | Buy |
Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
Jul-26-23 | Reiterated | Citigroup | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-24-23 | Reiterated | BofA Securities | Buy |
May-24-23 | Reiterated | UBS | Buy |
Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-06-23 | Initiated | Jefferies | Hold |
Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
Nov-18-22 | Initiated | Credit Suisse | Outperform |
Sep-22-22 | Upgrade | UBS | Neutral → Buy |
May-23-22 | Initiated | SVB Leerink | Outperform |
Apr-06-22 | Resumed | Morgan Stanley | Overweight |
Mar-10-22 | Initiated | Daiwa Securities | Outperform |
Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
Dec-17-21 | Initiated | Goldman | Neutral |
Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
Dec-16-21 | Reiterated | BofA Securities | Buy |
Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
Jul-27-21 | Resumed | Truist | Buy |
Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Nov-10-20 | Resumed | Bernstein | Mkt Perform |
Sep-29-20 | Initiated | Berenberg | Hold |
Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
Apr-21-20 | Downgrade | UBS | Buy → Neutral |
Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-06-20 | Initiated | Mizuho | Neutral |
Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-17-19 | Resumed | BofA/Merrill | Buy |
May-28-19 | Initiated | Goldman | Buy |
Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
Mar-12-19 | Initiated | JP Morgan | Overweight |
Jan-23-19 | Initiated | UBS | Buy |
Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Oct-09-18 | Initiated | Guggenheim | Buy |
Oct-01-18 | Reiterated | SunTrust | Buy |
Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Jim Cramer Defends Eli Lilly and Company (LLY) Amid Concerns Over Drug Adherence, Cites Long-Term Health Potential - Yahoo Finance
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Parsons Capital Management Inc. RI Boosts Stake in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Verde Servicos Internacionais S.A. Takes $5.79 Million Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Eli Lilly and Company (NYSE:LLY) Cut to "Hold" at StockNews.com - MarketBeat
Eli Lilly and Company (LLY) to Release Earnings on Thursday - MarketBeat
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges - Investing.com
Eli Lilly and Company (NYSE:LLY) Trading Up 1.9%What's Next? - MarketBeat
Eli Lilly and Company (NYSE:LLY) Trading Up 0%Here's What Happened - MarketBeat
Eli Lilly Stock's Correction Brings Opportunity (NYSE:LLY) - Seeking Alpha
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment - Indianapolis Business Journal
Is Eli Lilly and Company (LLY) the Best Stock to Buy in 2025 for Beginners? - Insider Monkey
Eli Lilly Bid to Upset Age-Bias Class Test Meets Leery 7th Cir. - Bloomberg Law
Stock Quote & Chart | Eli Lilly and Company - Investors | Eli Lilly and Company
Why Are Hedge Funds Bullish on Eli Lilly and Company (NYSE:LLY)? - Insider Monkey
This is where: Purdue and Lilly are partnering on a shared mission to improve lives worldwide - The Persistent Pursuit
What Does the Future Hold for Eli Lilly? - MarketBeat
Assessing Eli Lilly: Insights From 7 Financial Analysts - Benzinga
Eli Lilly's SWOT analysis: stock poised for growth amid challenges - Investing.com
Eli Lilly's planned $3 billion investment in Pleasant Prairie called a ‘watershed moment’ for local economy - BizTimes Milwaukee
Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer - GlobeNewswire Inc.
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief - FiercePharma
Eli Lilly Appeal Tests Access to Age Bias, Wage Class Litigation - Bloomberg Law
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance
Bernstein maintains Eli Lilly stock Outperform, $1,100 target - Investing.com
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It. - The Motley Fool
Why Eli Lilly Stock Topped the Market Today - The Motley Fool
Lilly’s Zepbound outpaces Wegovy as December logs 212 trial updates - BioWorld Online
BofA reiterates Eli Lilly buy rating, $997 target - Investing.com
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY) - StreetInsider.com
Eli Lilly stock dips on Novo Nordisk's rival drug data - Investing.com
Is Now The Time To Put Eli Lilly (NYSE:LLY) On Your Watchlist? - Yahoo Finance
Neurocrine Biosciences Taps Former Eli Lilly Executive to Lead Drug Development and Device Innovation - StockTitan
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement - Investors | Eli Lilly and Company
Is Lilly Stock A Sell After Tumbling On Its Guidance Cut? - Investor's Business Daily
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble? - MSN
The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's - Zacks Investment Research
Top Analyst Reports for Eli Lilly, Exxon Mobil & Costco - Yahoo Finance
Why Is Eli Lilly and Company (LLY) Among the Best Large-Cap Value Stocks to Buy in 2025? - Insider Monkey
M.E. Allison & CO. Inc. Purchases New Stake in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases - Benzinga
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says - Fortune
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound - Benzinga
Eli Lilly: Market Overreacted (NYSE:LLY) - Seeking Alpha
Should You Buy the Dip in Eli Lilly Stock Right Now? - AOL
Is Eli Lilly And Co. (LLY) Splitting in the Near Future? - Insider Monkey
Eli Lilly, Avago lead market cap stock movers on Monday - Investing.com
Eli Lilly and Company (NYSE:LLY) Trading Down 4.1%Here's What Happened - MarketBeat
Eli Lilly, Nvidia among Monday's market cap stock movers - Investing.com
Lilly, Merck team with Purdue University to pioneer new drug production methods - FiercePharma
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):